News

Patients with a co-infection of Clostridium difficile and ulcerative colitis or Crohn’s disease have higher rates of in-hospital mortality and health care resource utilization.

Students battle stigma, uncertainty, and hurricanes to return home with an MD. But is it as bad as advertised?

The results suggest that this approach could streamline the diagnosis of diabetes, losing the need for the same elevated test needing to be repeated in a new blood sample.

Researchers found nonfatal opioid overdose survivors have a 20-fold greater mortality rate in the months following their incident. However, designated therapies for such patients have been proven to counter that risk.

Updated 24-week data was released from patients treated with the 900 mg dose of voxelotor in the ongoing HOPE-KIDS 1 Study, a phase 2a open-label study in adolescents ages 6 to 17 years with sickle cell disease (SCD).

Clinical data demonstrate that CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina.

The first patient is anticipated to be enrolled in the third quarter of 2018, and topline results will be expected by the beginning of 2020.

Updated interim data from Affimed NV’s phase 1b dose-escalation study evaluating AFM13 for the treatment of relapsed/refractory Hodgkin Lymphoma were released at the 23rd Congress of the European Hematology Association.

The condition is characterized by a display of persistent or recurrent gaming behavior, online or offline, and can appear in continuous, episodic, and recurrent patterns.

The Qualified Infections Disease Product (QIDP) designation gives ACX-362E access to incentives including Priority Review and eligibility for Fast track status.

This minimally invasive procedure provides additional options for the patient population suffering with sacral insufficiency fractures.

New immigration policies are affecting the health of thousands of migrant children, and physicians want the world to know about it.

The triad of companies said that, while the details have yet to be hammered out, the initiative will be long-term and “free from profit-making incentives and constraints.”

Alexion Pharmaceuticals, Inc. has submitted a BLA to the FDA for approval of ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

The medical group’s primary care offices managed to reduce wasted patient minutes by 7.6% through efforts to streamline and shore up patient throughput.

Many antimicrobials prescribed after Clostridium difficile infection are prescribed inappropriately.

An interactive parent-child therapy appears to reduce depression in children 3-6 years old. Interestingly, the therapy also improved symptoms of clinical depression in participating parents.

New data from the FUTURE 5 study show that the interleukin-17A antagonist slows the progression of joint structural damage compared to placebo.

Sickle Cell Disease Association of America (SCDAA) and Emmaus Life Sciences partner in an effort to combat sickle cell disease.

Make-A-Wish New Jersey celebrated 35 years of wish granting in the Garden State at its annual Gala Thursday night, filled with celebrity surprises, a wish granted, and a historic first-time meeting, and musical entertainment by Max Weinberg of the E-Street Band and Friends.

In honor of World Sickle Cell Awareness Day, we’ve rounded up the big treatment advances made this year thus far for sickle cell disease.

Amphivena Therapeutics has released initial data from the dose escalation portion of the first-in-human phase 1 trial (AMV564-101, NCT03144245) evaluating AMV564 in patients with relapsed and/or refractory acute myeloid leukemia (AML).

Between 2013 and 2016, diagnoses of major depression jumped by 33% overall, and by 63% and 47% among adolescents and millennials, respectively.

Researchers have discovered how a genetic mutation in individuals with hypokalemic periodic paralysis impacts muscle function and may have found a possibility for treatment.

A new analysis shows a combination of ombitasvir/paritaprevir, ribavirin, and dasabuvir is safe and effective among older patients with HCV and cirrhosis.

Ray Comenzo, MD, highlights promising ANDROMEDA phase 3 trial, which evaluated the efficacy of subcutaneous daratumumab and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as a combination therapy for newly diagnosed light chain (AL) amyloidosis patients.

Half of patients admitted to an emergency department for uncontrolled asthma had unknowingly emptied their bronchodilator inhaler, according to a recent study.

Despite having worse vision and more CST than participants without baseline MNP upon entering the trials, patients experienced increased visual acuity along with improvements in anatomy.

Importantly, they are not directed toward ophthalmologists, but at general physicians and public healthcare professionals.

The software is now indicated to assist physicians treating patients with T1D who use insulin pumps and continuous glucose monitoring.